N/A N=170 Quantifying the Efficacy and Role of Service Dogs for Military Veterans With PTSD
Post Traumatic Stress Disorder
Primary: PTSD Severity and Symptoms Via Self-report — 41.9; 51.7 units on a scale — p=<.001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=199 Alvopem® (Pemetrexed) Safety Assessment
Non Small Cell Lung Cancer · Malignant Pleural Mesothelioma
Primary: Safety Assessment Including Treatment-related Adverse Events (Number of Participants Who Experienced at Least One Adverse Event (AE) or One Serious Adverse Event (SAE))…
N/A N=576 Feasibility Study of a Web-based Program to Help Parents of Middle School Students Effectively Communicate With Their Children About Substance Use
Substance Use · Parenting · Communication
Primary: Change From Baseline in Parent Report of Parent-child Communication Quality at Week 4 — 3.12; 3.11 score on a scale — p=0.77
N/A N=38 Coil Assisted Flow Diversion Safety and Performance Study
Intracranial Aneurysm
Primary: The Proportion of Subjects With Death of Any Non-accidental Cause or Any Major Disabling Stroke After Treatment or Major Disabling Stroke or Death Due to Neurological…
Phase 2 N=35 Oophorectomy, Estrogen Therapy and Cardiovascular Disease Risk in Young Women
Cardiovascular Risk Reduction
Primary: Arterial Stiffness — 10.1; 14.8; 6.4; 12.7 mm Hg
Phase 2 N=12 Pembrolizumab With and Without Radiotherapy for Non-Small Cell Lung Cancer
Non Small Cell Lung Cancer
Primary: Change in the Mean Number of Infiltrating Absolute Cluster of Differentiation 3 (CD3+) T Cells/ μm2 — 2976.00007; 3768.74373 CD3+ T cells/ μm2
N/A N=393 Smoking Prevention Through Social Connections Among Adolescents - ASPIRE
Tobacco Use Behavior
Primary: Susceptibility to Vaping — 66; 118 Participants — p=0.80
Phase 4 N=200 Diabetes Remote Intervention to improVe Use of Evidence-based Medications
Cardiovascular Diseases · Diabetes
Primary: Number of Patients With Prescriptions of SGLT2i or GLP1-RA at Any Time — 81; 47 Participants
Phase 1 N=41 A Study of Olaratumab (LY3012207) Plus Pembrolizumab in Participants With Advanced or Metastatic Soft Tissue Sarcoma
Soft Tissue Sarcoma
Primary: Number of Participants With Olaratumab Dose Limiting Toxicities (DLTs) — 0; 0; 0 participants
N/A N=268 ElderTree Smart System for Older Adults
Chronic Pain
Primary: Change in Patient-Reported Outcomes Measurement Information System (PROMIS) Short Form v2.1 - Pain Interference Score — 58.44; 59.57; 59.19; 57.94 score on a scale
Phase 3 N=193 Pediatric Arthritis Study of Certolizumab Pegol
Polyarticular-course Juvenile Idiopathic Arthritis (JIA)
Primary: Certolizumab Pegol (CZP) Plasma Concentration Level at Week 16 — 1.6166; 9.2277; 13.8928; 22.9060 ug/ml
N/A N=400 Investigation of Clot in Ischemic Stroke and Hematoma Evacuation
Ischemic Stroke · Intracranial Hematoma
Primary: Clot Specimen Histology — 373; 12 Count of specimen
Early Phase 1 N=13 Non-Opioid Pramipexole and Pain
Chronic Pain
Primary: Brief Pain Inventory Score — 8; 6.7 score on a scale
N/A N=102 Role of a Novel Exercise Program to Prevent Post-thrombotic Syndrome
Acute Deep Vein Thrombosis
Primary: 2-year Change in Villalta Score — -1.5; -0.5 units on a scale — p=0.34
N/A N=1,988 Strategic Antiretroviral Therapy and HIV Testing for Youth in Rural Africa
HIV
Primary: Effectiveness of SEARCH Youth Intervention — 88.2; 80.5; 90.9; 85.3 % of participants — p=0.0019